Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879

David I. Quinn, Denice D. Tsao-Wei, Przemyslaw Twardowski, Ana M. Aparicio, Paul Frankel, Gurkamal Chatta, John J. Wright, Susan G. Groshen, Stella Khoo, Heinz Josef Lenz, Primo N. Lara, David R. Gandara, Edward Newman

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879'. Together they form a unique fingerprint.

Medicine & Life Sciences